An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK515.00.

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Wood’s ETFs tend to hold 30-40 stocks and have rather high concentrations in their largest holdings. Asset management company Ark Invest offers nine different investment funds, eight of which ...

Despite these challenges, Novo Holdings remains committed to life sciences, a sector that faces hurdles but is supported by strong long-term trends, Kutay told NDTV Profit at the World Economic Forum ...

The S&P 500 closed lower after hitting new records on Friday, as investors took some profit to end a solid week centered on President Donald Trump 's return to the White House.